GYRE
Gyre Therapeutics Inc

9,515
Loading...
Loading...
News
all
press releases
Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates
Arcellx (ACLX) delivered earnings and revenue surprises of +8.74% and -54.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
More News
News Placeholder
Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates
Prothena (PRTA) delivered earnings and revenue surprises of -67.57% and -79.20%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates
chainwire·4mo ago
News Placeholder
Gyre Therapeutics Seeks Compliance Amid Board Reshuffle
Gyre Therapeutics (GYRE) has shared an announcement. Gyre Therapeutics, Inc. has reported a vacancy on its Audit Committee following the resignatio...
TipRanks Financial Blog·1y ago
News Placeholder
Gyre Therapeutics (GYRE, $15.85) price exceeded its 50-day Moving Average on April 01, 2024
This price move could indicate a change in the trend, and may be a sell signal for investors...
Tickeron - Stocks·1y ago
News Placeholder
Gyre Therapeutics Inc (GYRE) Announces Full Year 2023 Financial Outcomes and Business Progress
Transformational Year with Strategic Shifts and Clinical AdvancesRelated Stocks: GYRE...
GuruFocus·1y ago
News Placeholder
Gyre Therapeutics GAAP EPS of -$1.41, revenue of $113.5M
Gyre Therapeutics GAAP EPS of -$1.41, revenue of $113.5M...
SeekingAlpha.com: All News·1y ago
News Placeholder
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Data readout from Phase 3 clinical trial in the People's Republic of China ( PRC ) evaluating F351 for the treatment of CHB-associated liver fibrosis expected by early 2025 U.S. Phase 2a clinical...
Globe Newswire·1y ago
News Placeholder
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ( Gyre ) (Nasdaq: GYRE), a clinical-stage biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ...
Globe Newswire·1y ago
News Placeholder
Gyre Therapeutics (GYRE, $16.76) price exceeded its 50-day Moving Average on March 15, 2024
This price move could indicate a change in the trend, and may be a sell signal for investors...
Tickeron - Stocks·2y ago

Latest GYRE News

View

Advertisement. Remove ads.

Advertisement. Remove ads.